Brief: Pliant Therapeutics Announces Positive Safety And Exploratory Efficacy Data Phase 2A Of Bexotegrast

Pliant Therapeutics

04/02/2024 20:38

Feb 5 (Reuters) - Pliant Therapeutics Inc  PLRX.O :
    * PLIANT THERAPEUTICS ANNOUNCES POSITIVE SAFETY AND
EXPLORATORY
EFFICACY DATA FROM THE INTEGRIS-PSC PHASE 2A TRIAL OF
BEXOTEGRAST 320 MG IN PATIENTS WITH PRIMARY SCLEROSING
CHOLANGITIS AND SUSPECTED LIVER FIBROSIS
    * PLIANT THERAPEUTICS - BEXOTEGRAST ) AT 320 MG WAS WELL
TOLERATED
OVER 12 WEEKS OF TREATMENT WITH NO DRUG-RELATED SEVERE OR
SERIOUS ADVERSE EVENTS
    * 320 MG DATA CONTINUE TO DEMONSTRATE ANTIFIBROTIC EFFECTS
OF
BEXOTEGRAST, CONSISTENT WITH PREVIOUS FINDINGS
    * PLIANT THERAPEUTICS-BEXOTEGRAST AT 320 MG REDUCED LIVER
FIBROSIS
MARKERS ELF, PRO-C3
    * PLIANT THERAPEUTICS-BEXOTEGRAST AT 320 MG SHOWED
IMPROVEMENTS IN
HEPATOCYTE FUNCTION, BILE FLOW BY CONTRAST MRI RELATIVE TO
PLACEBO AT WEEK 12
    * PLIANT THERAPEUTICS - PRIMARY ENDPOINT OF INTEGRIS-PSC
TRIAL IS
EVALUATION OF SAFETY , TOLERABILITY OF BEXOTEGRAST
    * PLIANT THERAPEUTICS - SECONDARY ENDPOINT IS AN ASSESSMENT
OF ITS
PHARMACOKINETICS

Source text for Eikon:  ID:nGNX3qZ6Dt 
Further company coverage:  PLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))